What is HEALTHLYNKED CORP NEW's earnings per share (EPS)?

HEALTHLYNKED CORP NEW (HLYKD) reported diluted earnings per share of $-1.16 for fiscal year 2025. This represents a 46.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

HEALTHLYNKED CORP NEW Financials

HLYKD

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows HEALTHLYNKED CORP NEW (HLYKD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI HLYKD FY2025 2026-04-22

Shrinking sales are no longer clearing an overhead-heavy cost base, leaving the company reliant on external funding to keep operating.

Even though operating cash burn narrowed to -$1.7M in FY2025 from -$4.1M in FY2023, balance-sheet strain still intensified because assets kept shrinking while equity stayed deeply negative. That combination suggests the lower burn reflects a smaller operating footprint more than a business that has begun to finance itself internally.

By FY2025, SG&A was almost the same size as revenue—$2.0M against $2.1M—so the company still has to clear a large fixed overhead hurdle before operations can approach break-even. The improvement in operating loss versus FY2024 therefore looks more like cost cutting around a smaller business than scale benefits.

Cash ended FY2025 at $37K even after a financing inflow of $1.5M, which shows outside capital is still doing work that operations are not. With a 0.2x current ratio and negative equity, near-term obligations are being carried more by liabilities than by a replenished asset base.

Financial Health Signals

Financial Profile 2/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of HEALTHLYNKED CORP NEW's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

HEALTHLYNKED CORP NEW has an operating margin of -102.3%, meaning the company retains $-102 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -155.5% the prior year.

Growth

HEALTHLYNKED CORP NEW's revenue declined 31.3% year-over-year, from $3.0M to $2.1M. This contraction results in a growth score of 0/100.

Leverage

HEALTHLYNKED CORP NEW has elevated debt relative to equity (D/E of -1.30), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 14/100, reflecting increased financial risk.

Liquidity

HEALTHLYNKED CORP NEW's current ratio of 0.22 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Piotroski F-Score Weak

2/9

HEALTHLYNKED CORP NEW passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality Low Quality

0.52x

For every $1 of reported earnings, HEALTHLYNKED CORP NEW generates $0.52 in operating cash flow (-$1.7M OCF vs -$3.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$2.1M

YoY-31.3%

5Y CAGR-19.6%

HEALTHLYNKED CORP NEW generated $2.1M in revenue in fiscal year 2025. This represents a decrease of 31.3% from the prior year.

EBITDA

-$2.0M

YoY+54.2%

HEALTHLYNKED CORP NEW's EBITDA was -$2.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 54.2% from the prior year.

Net Income

-$3.3M

YoY+46.5%

HEALTHLYNKED CORP NEW reported -$3.3M in net income in fiscal year 2025. This represents an increase of 46.5% from the prior year.

EPS (Diluted)

$-1.16

YoY+46.8%

HEALTHLYNKED CORP NEW earned $-1.16 per diluted share (EPS) in fiscal year 2025. This represents an increase of 46.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$37K

YoY-51.3%

5Y CAGR-25.5%

HEALTHLYNKED CORP NEW held $37K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+1.6%

HEALTHLYNKED CORP NEW had 3M shares outstanding in fiscal year 2025. This represents an increase of 1.6% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-102.3%

YoY+53.2pp

5Y CAGR-52.2pp

HEALTHLYNKED CORP NEW's operating margin was -102.3% in fiscal year 2025, reflecting core business profitability. This is up 53.2 percentage points from the prior year.

Net Margin

-158.8%

YoY+45.0pp

5Y CAGR-65.0pp

HEALTHLYNKED CORP NEW's net profit margin was -158.8% in fiscal year 2025, showing the share of revenue converted to profit. This is up 45.0 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

HLYKD Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$2.1M-31.3%	$3.0M-47.4%	$5.7M-2.3%	$5.9M-9.8%	$6.5M+5.9%	$6.1M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$2.0M-33.0%	$3.0M-16.1%	$3.6M-20.8%	$4.6M-7.1%	$4.9M+60.9%	$3.1M
Operating Income	-$2.1M+54.8%	-$4.7M-12.7%	-$4.2M+52.1%	-$8.7M-62.4%	-$5.3M-73.5%	-$3.1M
Interest Expense	N/A	N/A	$21K	$0	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$3.3M+46.5%	-$6.1M-505.8%	-$1.0M+88.5%	-$8.8M+15.3%	-$10.4M-80.9%	-$5.8M
EPS (Diluted)	$-1.16+46.8%	$-2.18	$0.00+100.0%	$-0.04+20.0%	$-0.05-25.0%	$-0.04

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$423K+36.5%	$310K-20.2%	$389K-34.4%	$592K-23.5%	$774K+25.1%	$619K+4.9%	$590K-25.8%	$795K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$847K+86.8%	$454K-9.4%	$501K+10.8%	$452K-28.2%	$629K+15.2%	$546K-13.6%	$632K-26.7%	$861K
Operating Income	-$701K-32.0%	-$531K-0.2%	-$530K-21.6%	-$435K+29.5%	-$617K+17.5%	-$749K+55.2%	-$1.7M-54.8%	-$1.1M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$1.6M-139.7%	-$676K+20.6%	-$852K-21.5%	-$701K+33.3%	-$1.1M+14.6%	-$1.2M+37.7%	-$2.0M-28.1%	-$1.5M
EPS (Diluted)	$-0.56	N/A	$-0.30	$0.00+100.0%	$-0.37	N/A	$-0.70-6900.0%	$-0.01

HLYKD Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$1.7M-23.4%	$2.2M-48.1%	$4.3M-6.6%	$4.6M-57.2%	$10.7M+33.2%	$8.0M
Current Assets	$1.6M-5.5%	$1.6M+150.1%	$656K-69.4%	$2.1M-41.3%	$3.7M+804.6%	$404K
Cash & Equivalents	$37K-51.3%	$76K-69.2%	$247K+299.4%	$62K-98.1%	$3.3M+1929.6%	$162K
Inventory	$18K-59.8%	$45K-66.5%	$133K-30.9%	$193K+42.9%	$135K+41.7%	$95K
Accounts Receivable	N/A	N/A	$21K-71.1%	$72K-16.2%	$86K-1.0%	$87K
Goodwill	N/A	N/A	N/A	$320K-58.2%	$766K-33.3%	$1.1M
Total Liabilities	$7.5M+39.5%	$5.4M+54.0%	$3.5M-18.5%	$4.3M+22.2%	$3.5M-47.7%	$6.7M
Current Liabilities	$7.0M+49.5%	$4.7M+94.4%	$2.4M-30.6%	$3.5M+81.2%	$1.9M-60.7%	$4.9M
Long-Term Debt	N/A	N/A	N/A	$45K-55.6%	$101K+464.3%	$18K
Total Equity	-$5.8M-84.1%	-$3.1M-488.9%	$805K+155.9%	$314K-95.6%	$7.2M+433.6%	$1.4M
Retained Earnings	-$50.5M-4.9%	-$48.2M-14.6%	-$42.0M-2.5%	-$41.0M-27.4%	-$32.2M-47.8%	-$21.8M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$1.6M-4.5%	$1.7M-3.5%	$1.8M-4.5%	$1.8M-10.2%	$2.1M-7.5%	$2.2M-19.4%	$2.8M-28.5%	$3.9M
Current Assets	$1.5M-0.8%	$1.6M+0.6%	$1.5M-1.0%	$1.6M-0.5%	$1.6M-4.5%	$1.6M-10.0%	$1.8M-9.0%	$2.0M
Cash & Equivalents	$24K-35.4%	$37K+240.4%	$11K-46.0%	$20K-9.3%	$22K-70.8%	$76K+409.7%	$15K-91.3%	$173K
Inventory	$18K+2.8%	$18K-43.8%	$32K+15.9%	$28K-14.5%	$32K-27.8%	$45K-43.3%	$79K-18.3%	$96K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	$26K-33.7%	$39K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$8.6M+15.9%	$7.5M+3.7%	$7.2M+9.0%	$6.6M+6.6%	$6.2M+15.7%	$5.4M+14.1%	$4.7M+9.5%	$4.3M
Current Liabilities	$8.2M+16.9%	$7.0M+4.0%	$6.7M+10.1%	$6.1M+9.4%	$5.6M+19.4%	$4.7M+23.2%	$3.8M+12.1%	$3.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$7.0M-21.9%	-$5.8M-6.0%	-$5.4M-14.3%	-$4.8M-14.9%	-$4.1M-32.2%	-$3.1M-61.9%	-$1.9M-355.3%	-$425K
Retained Earnings	-$52.2M-3.3%	-$50.5M+0.5%	-$50.8M-1.7%	-$49.9M-1.4%	-$49.2M-2.2%	-$48.2M-2.6%	-$46.9M-4.4%	-$45.0M

HLYKD Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$1.7M+51.0%	-$3.5M+15.7%	-$4.1M+5.0%	-$4.4M-15.7%	-$3.8M-78.1%	-$2.1M
Capital Expenditures	N/A	$3K+73.2%	$2K-93.6%	$24K+22.4%	$19K-23.0%	$25K
Free Cash Flow	N/A	-$3.5M+15.7%	-$4.1M+5.5%	-$4.4M-15.8%	-$3.8M-76.9%	-$2.1M
Investing Cash Flow	$125K-70.4%	$422K-88.0%	$3.5M+743.6%	-$545K-59.6%	-$341K-118.8%	$1.8M
Financing Cash Flow	$1.5M-46.6%	$2.9M+252.0%	$824K-50.9%	$1.7M-76.8%	$7.2M+1929.3%	$357K
Dividends Paid	$0	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	$8K	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$222K+47.1%	-$419K+5.6%	-$444K-6.4%	-$418K+3.5%	-$433K+41.8%	-$744K+28.3%	-$1.0M-20.8%	-$859K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	$0	$0	$0
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	-$744K+28.3%	-$1.0M-20.8%	-$859K
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	$425K	$0	$0
Financing Cash Flow	$209K-34.9%	$321K-26.3%	$435K+4.7%	$415K+9.7%	$379K-0.3%	$380K-56.8%	$879K-12.8%	$1.0M
Dividends Paid	$36K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

HLYKD Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-102.3%+53.2pp	-155.5%-82.9pp	-72.5%+75.3pp	-147.8%-65.8pp	-82.0%-32.0pp	-50.1%
Net Margin	-158.8%+45.0pp	-203.8%-186.1pp	-17.7%+132.8pp	-150.5%+9.8pp	-160.3%-66.4pp	-93.8%
Return on Equity	N/A	N/A	-125.8%+2677.8pp	-2803.5%-2659.0pp	-144.5%+281.8pp	-426.3%
Return on Assets	-192.7%+83.1pp	-275.8%-252.2pp	-23.6%+168.8pp	-192.5%-95.1pp	-97.4%-25.7pp	-71.7%
Current Ratio	0.22-0.1	0.35+0.1	0.27-0.3	0.62-1.3	1.90+1.8	0.08
Debt-to-Equity	-1.30+0.4	-1.71-6.0	4.32+4.2	0.14+0.1	0.010.0	0.01
FCF Margin	N/A	-116.2%-43.8pp	-72.5%+2.4pp	-74.9%-16.6pp	-58.3%-23.4pp	-34.9%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-165.5%+5.7pp	-171.2%-34.9pp	-136.3%-62.8pp	-73.5%+6.2pp	-79.7%+41.2pp	-121.0%+162.2pp	-283.2%-147.4pp	-135.8%
Net Margin	-382.9%-164.8pp	-218.1%+1.1pp	-219.2%-100.9pp	-118.3%+17.4pp	-135.7%+63.0pp	-198.8%+135.6pp	-334.4%-140.6pp	-193.8%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-99.7%-60.0pp	-39.7%+8.5pp	-48.3%-10.3pp	-37.9%+13.2pp	-51.1%+4.3pp	-55.3%+16.2pp	-71.5%-31.6pp	-39.9%
Current Ratio	0.19-0.0	0.220.0	0.23-0.0	0.25-0.0	0.28-0.1	0.35-0.1	0.48-0.1	0.59
Debt-to-Equity	-1.23+0.1	-1.30+0.0	-1.32+0.1	-1.39+0.1	-1.50+0.2	-1.71+0.7	-2.43+7.7	-10.09
FCF Margin	N/A	N/A	N/A	N/A	N/A	-120.1%+55.6pp	-175.7%-67.7pp	-108.0%

Note: Shareholder equity is negative (-$5.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.22), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Frequently Asked Questions

What is HEALTHLYNKED CORP NEW's annual revenue?

HEALTHLYNKED CORP NEW (HLYKD) reported $2.1M in total revenue for fiscal year 2025. This represents a -31.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is HEALTHLYNKED CORP NEW's revenue growing?

HEALTHLYNKED CORP NEW (HLYKD) revenue declined by 31.3% year-over-year, from $3.0M to $2.1M in fiscal year 2025.

Is HEALTHLYNKED CORP NEW profitable?

No, HEALTHLYNKED CORP NEW (HLYKD) reported a net income of -$3.3M in fiscal year 2025, with a net profit margin of -158.8%.

What is HEALTHLYNKED CORP NEW's EBITDA?

HEALTHLYNKED CORP NEW (HLYKD) had EBITDA of -$2.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is HEALTHLYNKED CORP NEW's operating margin?

HEALTHLYNKED CORP NEW (HLYKD) had an operating margin of -102.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is HEALTHLYNKED CORP NEW's net profit margin?

HEALTHLYNKED CORP NEW (HLYKD) had a net profit margin of -158.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is HEALTHLYNKED CORP NEW's operating cash flow?

HEALTHLYNKED CORP NEW (HLYKD) generated -$1.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are HEALTHLYNKED CORP NEW's total assets?

HEALTHLYNKED CORP NEW (HLYKD) had $1.7M in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does HEALTHLYNKED CORP NEW have outstanding?

HEALTHLYNKED CORP NEW (HLYKD) had 3M shares outstanding as of fiscal year 2025.

What is HEALTHLYNKED CORP NEW's current ratio?

HEALTHLYNKED CORP NEW (HLYKD) had a current ratio of 0.22 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is HEALTHLYNKED CORP NEW's debt-to-equity ratio?

HEALTHLYNKED CORP NEW (HLYKD) had a debt-to-equity ratio of -1.30 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is HEALTHLYNKED CORP NEW's return on assets (ROA)?

HEALTHLYNKED CORP NEW (HLYKD) had a return on assets of -192.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is HEALTHLYNKED CORP NEW's cash runway?

Based on fiscal year 2025 data, HEALTHLYNKED CORP NEW (HLYKD) had $37K in cash against an annual operating cash burn of $1.7M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is HEALTHLYNKED CORP NEW's debt-to-equity ratio negative or unusual?

HEALTHLYNKED CORP NEW (HLYKD) has negative shareholder equity of -$5.8M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is HEALTHLYNKED CORP NEW's Piotroski F-Score?

HEALTHLYNKED CORP NEW (HLYKD) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are HEALTHLYNKED CORP NEW's earnings high quality?

HEALTHLYNKED CORP NEW (HLYKD) has an earnings quality ratio of 0.52x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is HEALTHLYNKED CORP NEW?

HEALTHLYNKED CORP NEW (HLYKD) scores 2 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.